Aislinn Antrim, MA, Assistant Managing Editor

The findings from the phase 3 KEYNOTE-091 trial mark the first positive study for pembrolizumab in adjuvant stage IB-IIIA non-small cell lung cancer.

Approximately 400,000 women undergo breast implant surgeries each year in the United States, and selecting an implant is an important and personal part of the process.

Across the trials, abrocitinib demonstrated a consistent safety profile and profound improvements in skin clearance, extent of disease, and severity.

The Microbiome Health Index for post-Antibiotic dysbiosis was developed to improve the understanding of and manage the risks associated with antibiotic administration.

The findings could help clinicians tailor the use of early antibiotics in newborns because only infants deemed at risk for infection should receive antibiotics.

The observed increase in patient age at the time of relapse makes the findings even more impressive because longer survival is typically associated with younger age at the time of relapse.

Olive oil consumption increased from 1.6 grams per day in 1990 to approximately 4 grams per day in 2010.

C-CAR039 showed positive efficacy and safety data in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

Knocking down MAPK4 resulted in the cells’ increased sensitivity to PI3K inhibitors and reduced breast cancer growth.

Responses elicited by the pneumococcal vaccine for all 20 serotypes were similar whether administered with the COVID-19 vaccine or with placebo.

The FDA granted priority review to the combination of relatlimab and nivolumab in September 2021 based on the results of this study.

Study strongly supports the CDC’s guidance that booster shots are appropriate for anyone ages 16 and older, and that mRNA vaccines are preferred.

Incorporating mental distress screenings during cancer care have been historically difficult, despite the fact that these patients tend to be vulnerable to mental health challenges.

The FGF1 hormone regulates blood glucose by inhibiting fat breakdown, although it works differently than insulin.

There were no instances of participants withdrawing from the study due to an adverse event caused by psilocybin in the treatment of mental health conditions.

The metabolic protein SIRT3 reduces the pools of amino acids that cells use to make proteins and otherwise fuel their growth.

The approval marks the first small interfering RNA therapy for low-density lipoprotein cholesterol reduction.

The existing EUA was also amended to reduce the time for booster dose administration from a minimum of 6 months to at least 5 months following completion of the primary COVID-19 vaccine series.

The Breakthrough Therapy Designation was granted based on data from the dose escalation portion of 2 expansion cohorts of a 3-cohort phase 1 study.

More transparent drug pricing could improve patient care.

Modern technology is crucial to the provision of home infusions.

The first and only orally disintegrating tablet form of glycopyrrolate, the product will be launched in early 2022.

Mean changes from baseline in weight, fasting glucose, total cholesterol, triglycerides, and low-density lipoprotein cholesterol were similar between lumateperone and placebo.

The updated oath has entered into the modern era with more inclusive and contemporary language.

Multiple myeloma has remarkable genetic heterogeneity, which can make it challenging to identify proper prognostication and clinical management for patients.

The treatment was first approved in 2013 for adults as a 1500 mg course of treatment, administered as 2 doses of 750 mg each separated by at least 7 days.

The new analysis includes approximately 1100 women without type 1 or type 2 diabetes (T2D) who subsequently gave birth at least once during the 25-year study period, which ended in 2011.

The safety profile observed in patients with active psoriatic arthritis administered upadacitinib was consistent with the safety profile observed in patients with rheumatoid arthritis.

At week 16, 56.4% of patients receiving tofacitinib achieved an Assessment in SpondyloArthritis International Society 20 response.

Serotypes 22F, 33F, and 3 represent more than a quarter of invasive pneumococcal disease in children under the age of 5